Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1997

View Archived Issues

Ferring permitted to resume marketing of Repronex

PharmaPrint submits IND for herbal BPH treatment

Astra: 1997 half-year highlights

Terrapin and Taiho sign development agreement for anticancer agent

New biotech company formed to combat cardiovascular diseases

FDA proposes to require pediatric data on drugs

U.S. patent issued for Candida albicans treatment method

Spanish scientists discover anxiolytic CCKA antagonist

Phase I trial of DiffGAM completed successfully

Sequana, Boehringer Mannheim closer to elucidating genetic basis of osteoporosis

Vasopressin agonist from Otsuka

Phenobarbital ineffective in stopping brain bleeding in neonates

Twinrix now available for pediatric use

Novo Nordisk: 1997 half-year highlights

GalaGen starts Diffistat-G phase II trial

VEGF RTK inhibitors in the pipeline at Zeneca

Clinical trial results announced for novel incontinence therapeutic

New treatment for osteoarthritis approved for marketing in U.S.

Patents for collagen markers issued to Ostex

Drug discovery agreement forged by Procept, Abbott

Onyx, W-L collaborate on antiinflammatory and immunomodulating agents

SmithKline Beecham donates Havrix vaccine to flood areas

Glaxo Wellcome discloses a new series of thrombin inhibitors

Sporidin-G trial put on hold

IRIS licenses patents to TOA

Delmopinol inhibits gingivitis in extreme rates of plaque formation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...